AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF BRIDGEBIOX PHARMA, LLC, a Delaware Limited Liability Company Dated as of August 16, 2024Limited Liability Company Agreement • August 21st, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
This AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”) of BridgeBioX Pharma, LLC, a Delaware limited liability company (the “Company”), is made and entered into as of August 16, 2024, by and among each of the Persons set forth on Schedule A.
TRANSACTION AGREEMENTTransaction Agreement • August 21st, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • Delaware
This TRANSACTION AGREEMENT (this “Agreement”), dated as of August 16, 2024, is made by and among Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown (Aggregator) LP, Patient Square Bravo Aggregator, LP, SC US/E GROWTH FUND X MANAGEMENT, L.P., SC US/E Venture Fund XVIII Management, L.P., Frazier Life Sciences XI, L.P., Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., Cormorant Private Healthcare Fund IV, LP, Cormorant Private Healthcare Fund V, LP, Cormorant Global Healthcare Master Fund, LP, Aisling V Bridge Splitter LP, Kumar Haldea Revocable Trust (each, an “Investor” and collectively, the “Investors”), BridgeBio Pharma, Inc., a Delaware corporation (“BridgeBio” and together with the Investors, the “Members” and each a “Member”), Patient Square Bravo Aggregator, LP, Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, solely in
